Daniel Lindholm

Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

Lee, Sooji; Lindholm, Daniel; Sundström, Johan; Yon, Dong Keon

Ingår i Nature Medicine, s. 1454-1478, 2026

• DOI för Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

A deep learning ECG model for identification and localization of occlusion myocardial infarction

Gustafsson, Stefan; Ribeiro, Antônio H.; Gedon, Daniel; Abreu, Petrus E. O. G. B. et al.

Ingår i Nature Communications, 2026

• DOI för A deep learning ECG model for identification and localization of occlusion myocardial infarction
• Ladda ner fulltext (pdf) av A deep learning ECG model for identification and localization of occlusion myocardial infarction

Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

Lindholm, Daniel; Ribom, Gustav; Gustafsson, Stefan; Pol, Tymon et al.

Ingår i Journal of the American College of Cardiology, s. 1087-1090, 2026

• DOI för Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Eriksson, Jan W; Fanni, Giovanni; Lundqvist, Martin H.; Jansson, Stefan P. O. et al.

Ingår i Diabetes, obesity and metabolism, s. 1327-1338, 2026

• DOI för SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications
• Ladda ner fulltext (pdf) av SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Schumacher, Austin E; Lindholm, Daniel P; Murray, Christopher J L

Ingår i The Lancet, s. 1731-1810, 2025

• DOI för Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
• Ladda ner fulltext (pdf) av Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

Lee, Sooji; Lindholm, Daniel; Sundström, Johan; Yon, Dong Keon

Ingår i Nature Medicine, s. 1454-1478, 2026

• DOI för Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study

A deep learning ECG model for identification and localization of occlusion myocardial infarction

Gustafsson, Stefan; Ribeiro, Antônio H.; Gedon, Daniel; Abreu, Petrus E. O. G. B. et al.

Ingår i Nature Communications, 2026

• DOI för A deep learning ECG model for identification and localization of occlusion myocardial infarction
• Ladda ner fulltext (pdf) av A deep learning ECG model for identification and localization of occlusion myocardial infarction

Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

Lindholm, Daniel; Ribom, Gustav; Gustafsson, Stefan; Pol, Tymon et al.

Ingår i Journal of the American College of Cardiology, s. 1087-1090, 2026

• DOI för Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mortality (2004-2023)

SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Eriksson, Jan W; Fanni, Giovanni; Lundqvist, Martin H.; Jansson, Stefan P. O. et al.

Ingår i Diabetes, obesity and metabolism, s. 1327-1338, 2026

• DOI för SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications
• Ladda ner fulltext (pdf) av SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Schumacher, Austin E; Lindholm, Daniel P; Murray, Christopher J L

Ingår i The Lancet, s. 1731-1810, 2025

• DOI för Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
• Ladda ner fulltext (pdf) av Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Hay, Simon I; Lindholm, Daniel P; Gakidou, Emmanuela

Ingår i The Lancet, s. 1873-1922, 2025

• DOI för Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
• Ladda ner fulltext (pdf) av Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023

Stark, Benjamin A.; Ahmed, Anisuddin; Lindholm, Daniel; Marks-Hultström, Michael et al.

Ingår i Journal of the American College of Cardiology, s. 2167-2243, 2025

• DOI för Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023
• Ladda ner fulltext (pdf) av Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Mohsen, Naghavi; Sundström, Johan; Lindholm, Daniel P; Murray, Christopher J L

Ingår i The Lancet, s. 1811-1872, 2025

• DOI för Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023
• Ladda ner fulltext (pdf) av Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Kerr, Jessica A; Lindholm, Daniel P; Azzopardi, Peter S

Ingår i The Lancet, s. 785-812, 2025

• DOI för Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
• Ladda ner fulltext (pdf) av Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021

Steel, Nicholas; Lindholm, Daniel P; Newton, John N

Ingår i The Lancet Public Health, 2025

• DOI för Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021
• Ladda ner fulltext (pdf) av Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Naghavi, Mohsen; Kyu, Hmwe Hmwe; A, Bhoomadevi; Aalipour, Mohammad Amin et al.

Ingår i The Lancet, s. 1811-1872, 2025

• DOI för Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Ng, Marie; Lindholm, Daniel P; Vollset, S. E.

Ingår i The Lancet, s. 813-838, 2025

• DOI för Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
• Ladda ner fulltext (pdf) av Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Reply to 'The patterns and changes of heart failure treatment in the last years of life still need further study'

Sundström, Johan; Lindholm, Daniel P

Ingår i European Journal of Heart Failure, s. 180-181, 2025

• DOI för Reply to 'The patterns and changes of heart failure treatment in the last years of life still need further study'

Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study

Nilsson, Konrad; Lindholm, Daniel; Backes, Jenny; Bjursten, Henrik et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 641-649, 2024

• DOI för Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study
• Ladda ner fulltext (pdf) av Regional assessment of availability for transcatheter aortic valve implantation in Sweden: a long-term observational study

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Feigin, Valery L; Abate, Melsew Dagne; Abate, Yohannes Habtegiorgis; Abd ElHafeez, Samar et al.

Ingår i Lancet Neurology, s. 973-1003, 2024

• DOI för Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Vollset, Stein Emil; Ababneh, Hazim S; Abate, Yohannes Habtegiorgis; Abbafati, Cristiana et al.

Ingår i The Lancet, s. 2204-2256, 2024

• DOI för Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals

Sundström, Johan; Gustafsson, Stefan; Cars, Thomas; Lindholm, Daniel P

Ingår i European Journal of Heart Failure, s. 2443-2450, 2024

• DOI för Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals
• Ladda ner fulltext (pdf) av Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals

Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

Bhatt, Ankeet S.; Kosiborod, Mikhail N.; Claggett, Brian L.; Miao, Zi Michael et al.

Ingår i European Journal of Heart Failure, s. 2177-2188, 2023

• DOI för Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

The Maraca Plot: A Novel Visualization of Hierarchical Composite Endpoints.

Karpefors, Martin; Lindholm, Daniel; Gasparyan, Samvel B.

Ingår i Clinical Trials, s. 84-88, 2023

• DOI för The Maraca Plot: A Novel Visualization of Hierarchical Composite Endpoints.

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.

Kosiborod, Mikhail N.; Bhatt, Ankeet S.; Claggett, Brian L.; Vaduganathan, Muthiah et al.

Ingår i Journal of the American College of Cardiology, s. 460-473, 2023

• DOI för Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.

Operational Challenges and Mitigation Measures during the COVID-19 Pandemic-Lessons from DELIVER.

Bhatt, Ankeet S.; Lindholm, Daniel; Nilsson, Ann; Zaozerska, Natalia et al.

Ingår i American Heart Journal, s. 133-140, 2023

• DOI för Operational Challenges and Mitigation Measures during the COVID-19 Pandemic-Lessons from DELIVER.

IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.

Adamson, Carly; Welsh, Paul; Docherty, Kieran F.; de Boer, Rudolf A. et al.

Ingår i JACC. Heart failure, s. 291-304, 2023

• DOI för IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

Butt, Jawad H.; Dewan, Pooja; Merkely, Béla; Belohlávek, Jan et al.

Ingår i Annals of Internal Medicine, s. 820-830, 2022

• DOI för Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Ingår i Journal of the American College of Cardiology, s. 1775-1784, 2022

• DOI för Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Ingår i Journal of the American College of Cardiology, s. 1775-1784, 2022

• DOI för Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Butt, Jawad H.; Kondo, Toru; Jhund, Pardeep S.; Comin-Colet, Josep et al.

Ingår i Journal of the American College of Cardiology, s. 1705-1717, 2022

• DOI för Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Ingår i JAMA cardiology, s. 1259-1259, 2022

• DOI för Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Ostrominski, John W.; Vaduganathan, Muthiah; Claggett, Brian L.; de Boer, Rudolf A. et al.

Ingår i European Journal of Heart Failure, s. 1892-1901, 2022

• DOI för Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Dapagliflozin in Heart Failure with Improved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.

Vardeny, Orly; Fang, James C.; Desai, Akshay S.; Jhund, Pardeep S. et al.

Ingår i Nature medicine, s. 2504-2511, 2022

• DOI för Dapagliflozin in Heart Failure with Improved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.

Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: A Patient-Level, Pooled Meta-Analysis of DAPA-HF and DELIVER.

Jhund, Pardeep S.; Kondo, Toru; Butt, Jawad H.; Docherty, Kieran F. et al.

Ingår i Nature medicine, s. 1956-1964, 2022

• DOI för Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: A Patient-Level, Pooled Meta-Analysis of DAPA-HF and DELIVER.

Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.

Butt, Jawad H.; Kondo, Toru; Jhund, Pardeep S.; Comin-Colet, Josep et al.

Ingår i Journal of the American College of Cardiology, s. 1705-1717, 2022

• DOI för Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.

Dapagliflozin for Heart Failure According to Body Mass Index: The DELIVER Trial.

Adamson, Carly; Kondo, Toru; Jhund, Pardeep S.; de Boer, Rudolf A. et al.

Ingår i European Heart Journal, s. 4406-4417, 2022

• DOI för Dapagliflozin for Heart Failure According to Body Mass Index: The DELIVER Trial.

Dapagliflozin and New York Heart Association Functional Class in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Ostrominski, John W.; Vaduganathan, Muthiah; Claggett, Brian L.; de Boer, Rudolf A. et al.

Ingår i European Journal of Heart Failure, s. 1892-1901, 2022

• DOI för Dapagliflozin and New York Heart Association Functional Class in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.

Peikert, Alexander; Martinez, Felipe A.; Vaduganathan, Muthiah; Claggett, Brian L. et al.

Ingår i Circulation Heart Failure, 2022

• DOI för Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.

Cunningham, Jonathan W.; Vaduganathan, Muthiah; Claggett, Brian L.; Kulac, Ian J. et al.

Ingår i Journal of the American College of Cardiology, s. 1302-1310, 2022

• DOI för Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.

Docherty, Kieran F.; Simpson, Joanne; Jhund, Pardeep S.; Inzucchi, Silvio E. et al.

Ingår i JACC. Heart failure, s. 104-118, 2022

• DOI för Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.

Docherty, Kieran F.; Welsh, Paul; Verma, Subodh; De Boer, Rudolf A. et al.

Ingår i Circulation, s. 980-994, 2022

• DOI för Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.

Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.

Berg, David D.; Docherty, Kieran F.; Sattar, Naveed; Jarolim, Petr et al.

Ingår i Circulation, s. 158-169, 2022

• DOI för Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA- HF Trial

Butt, Jawad H.; Dewan, Pooja; Merkely, Bela; Belohlavek, Jan et al.

Ingår i Annals of Internal Medicine, s. 820-830, 2022

• DOI för Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA- HF Trial

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.

Butt, Jawad H.; Jhund, Pardeep S.; Belohlavek, Jan; de Boer, Rudolf A. et al.

Ingår i Circulation, s. 1210-1224, 2022

• DOI för Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial.

Liver Tests and Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from DAPA-HF.

Adamson, Carly; Cowan, Lorna M.; de Boer, Rudolf A.; Diez, Mirta et al.

Ingår i European Journal of Heart Failure, s. 1856-1868, 2022

• DOI för Liver Tests and Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from DAPA-HF.

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Docherty, Kieran F.; Ogunniyi, Modele O.; Anand, Inder S.; Desai, Akshay S. et al.

Ingår i JACC. Heart failure, s. 52-64, 2022

• DOI för Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, Scott D.; McMurray, John J. V.; Claggett, Brian; de Boer, Rudolf A. et al.

Ingår i New England Journal of Medicine, s. 1089-1098, 2022

• DOI för Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Solomon, Scott D.; Vaduganathan, Muthiah; Claggett, Brian L.; de Boer, Rudolf A. et al.

Ingår i JACC. Heart failure, s. 184-197, 2022

• DOI för Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.

Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Myhre, Peder L.; Vaduganathan, Muthiah; Claggett, Brian L.; Miao, Zi Michael et al.

Ingår i JACC. Heart failure, s. 902-913, 2022

• DOI för Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Dapagliflozin Reduces Uric Acid Concentration, an Independent Predictor of Adverse Outcomes in DAPA-HF

McDowell, Kirsty; Welsh, Paul; Docherty, Kieran F.; Morrow, David A. et al.

Ingår i European Journal of Heart Failure, s. 1066-1076, 2022

• DOI för Dapagliflozin Reduces Uric Acid Concentration, an Independent Predictor of Adverse Outcomes in DAPA-HF

Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Vaduganathan, Muthiah; Claggett, Brian L.; Jhund, Pardeep; de Boer, Rudolf A. et al.

Ingår i Journal of the American College of Cardiology, s. 1775-1784, 2022

• DOI för Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.

Butt, Jawad H.; Adamson, Carly; Docherty, Kieran F.; de Boer, Rudolf A. et al.

Ingår i Circulation Heart Failure, 2021

• DOI för Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.

Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: An Analysis of DAPA-HF.

Dewan, Pooja; Docherty, Kieran F.; Bengtsson, Olof; de Boer, Rudolf A. et al.

Ingår i European Journal of Heart Failure, s. 632-643, 2021

• DOI för Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: An Analysis of DAPA-HF.

Efficacy of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Body Mass Index.

Adamson, Carly; Jhund, Pardeep S.; Docherty, Kieran F.; Belohlavek, Jan et al.

Ingår i European Journal of Heart Failure, s. 1662-1672, 2021

• DOI för Efficacy of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Body Mass Index.

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.

Butt, Jawad H.; Docherty, Kieran F.; Petrie, Mark C.; Schou, Morten et al.

Ingår i JAMA cardiology, s. 678-689, 2021

• DOI för Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.

Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Rationale and Design of the DELIVER Trial

Solomon, Scott D.; de Boer, Rudolf A.; DeMets, David; Hernandez, Adrian F. et al.

Ingår i European Journal of Heart Failure, s. 1217-1225, 2021

• DOI för Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Rationale and Design of the DELIVER Trial

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

Shen, Li; Kristensen, Soren Lund; Bengtsson, Olof; Bohm, Michael et al.

Ingår i JACC. Heart failure, s. 254-264, 2021

• DOI för Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA- HF.

Docherty, Kieran F.; Jhund, Pardeep S.; Anand, Inder; Bengtsson, Olof et al.

Ingår i Circulation, s. 1623-1632, 2020

• DOI för Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA- HF.

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.

Solomon, Scott D.; Jhund, Pardeep S.; Claggett, Brian L.; Dewan, Pooja et al.

Ingår i JACC. Heart failure, s. 811-818, 2020

• DOI för Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Jackson, Alice M.; Dewan, Pooja; Anand, Inder S.; Belohlavek, Jan et al.

Ingår i Circulation, s. 1040-1054, 2020

• DOI för Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

Kosiborod, Mikhail N.; Jhund, Pardeep S.; Docherty, Kieran F.; Diez, Mirta et al.

Ingår i Circulation, s. 90-99, 2020

• DOI för Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.

Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction

Lindholm, Daniel; Sarno, Giovanna; Erlinge, David; Svennblad, Bodil et al.

Ingår i Heart, 2019

• DOI för Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction

Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice The TASTE Trial in Perspective

Buccheri, Sergio; Sarno, Giovanna; Frobert, Ole; Gudnason, Thorarinn et al.

Ingår i Circulation. Cardiovascular Interventions, 2019

• DOI för Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice The TASTE Trial in Perspective

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study

Jernberg, Tomas; Lindholm, Daniel P; Hasvold, Lars Pål; Svennblad, Bodil et al.

Ingår i BMJ Open, 2019

• DOI för Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
• Ladda ner fulltext (pdf) av Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study

Factors associated with non-attendance at exercise-based cardiac rehabilitation

Borg, Sabina; Oberg, Birgitta; Leosdottir, Margret; Lindholm, Daniel et al.

Ingår i BMC Sports Science, Medicine and Rehabilitation, 2019

• DOI för Factors associated with non-attendance at exercise-based cardiac rehabilitation
• Ladda ner fulltext (pdf) av Factors associated with non-attendance at exercise-based cardiac rehabilitation

Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

Buccheri, Sergio; James, Stefan; Lindholm, Daniel; Frobert, Ole et al.

Ingår i European Heart Journal, s. 2607-2615, 2019

• DOI för Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)
• Ladda ner fulltext (pdf) av Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Patel, Riyaz S.; Tragante, Vinicius; Schmidt, Amand F.; McCubrey, Raymond O. et al.

Ingår i Circulation, 2019

• DOI för Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium
• Ladda ner fulltext (pdf) av Subsequent Event Risk in Individuals With Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Patel, Riyaz S.; Schmidt, Amand F.; Tragante, Vinicius; McCubrey, Raymond O. et al.

Ingår i Circulation, 2019

• DOI för Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data
• Ladda ner fulltext (pdf) av Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data

Normal radiological lymph node appearance in the thorax

Hansen, Tomas; Nilsson, M.; Lindholm, Daniel P; Sundström, Johan et al.

Ingår i Diseases of the esophagus, s. 1-6, 2019

• DOI för Normal radiological lymph node appearance in the thorax

Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.

Buccheri, Sergio; Sarno, Giovanna; Lagerqvist, Bo; Olivecrona, Göran et al.

Ingår i EuroIntervention, 2018

• DOI för Bioabsorbable polymer everolimus-eluting stents in patients with acute myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.

Caffeine and incidence of dyspnea in patients treated with ticagrelor

Lindholm, Daniel; James, Stefan K; Andersson, Jonas; Braun, Oscar Ö et al.

Ingår i American Heart Journal, s. 141-143, 2018

• DOI för Caffeine and incidence of dyspnea in patients treated with ticagrelor

Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General Population.

Lindholm, Daniel; Fukaya, Eri; Leeper, Nicholas J; Ingelsson, Erik

Ingår i Journal of the American Heart Association, 2018

• DOI för Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General Population.
• Ladda ner fulltext (pdf) av Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500 000 Individuals From the General Population.

Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.

Rao, Abhiram S; Lindholm, Daniel; Rivas, Manuel A; Knowles, Joshua W et al.

Ingår i Circulation, 2018

• DOI för Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.

Machine Learning For Improved Detection Of Myocardial Infarction In Patients Presenting With Chest Pain In The Emergency Department

Lindholm, Daniel; Holzmann, Martin

Ingår i Journal of the American College of Cardiology, s. 225-225, 2018

• DOI för Machine Learning For Improved Detection Of Myocardial Infarction In Patients Presenting With Chest Pain In The Emergency Department

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Lindholm, Daniel P; James, Stefan K; Gabrysch, Katja; Storey, Robert F et al.

Ingår i JAMA cardiology, s. 1160-1166, 2018

• DOI för Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study

Clinical and Genetic Determinants of Varicose Veins Prospective, Community-Based Study of approximate to 500 000 Individuals

Fukaya, Eri; Flores, Alyssa M.; Lindholm, Daniel P; Gustafsson, Stefan et al.

Ingår i Circulation, s. 2869-2880, 2018

• DOI för Clinical and Genetic Determinants of Varicose Veins Prospective, Community-Based Study of approximate to 500 000 Individuals

Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

Sarno, Giovanna; Lagerqvist, Bo; Olivecrona, Göran; Varenhorst, Christoph et al.

Ingår i Catheterization and cardiovascular interventions, s. 881-887, 2017

• DOI för Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

New Method for Assessing the Effect of Driving Distance to Hospital Care: Using OpenStreetMap Routing in Cardiovascular Research

Lindholm, Daniel P; James, Stefan K; Lagerqvist, Bo; Hlatky, Mark A et al.

Ingår i Circulation. Cardiovascular Quality and Outcomes, 2017

• DOI för New Method for Assessing the Effect of Driving Distance to Hospital Care: Using OpenStreetMap Routing in Cardiovascular Research

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Lindholm, Daniel; Lindbäck, Johan; Armstrong, Paul W.; Budaj, Andrzej et al.

Ingår i Journal of the American College of Cardiology, s. 813-826, 2017

• DOI för Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Lindholm, Daniel P; Hagström, Emil; James, Stefan K; Becker, Richard C et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
• Ladda ner fulltext (pdf) av Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome

Lindholm, Daniel P; James, Stefan K; Bertilsson, Maria; Becker, Richard C et al.

Ingår i Clinical Chemistry, s. 573-584, 2017

• DOI för Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome

Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

Johansson, Åsa; Eriksson, Niclas; Lindholm, Daniel; Varenhorst, Christoph et al.

Ingår i Human Molecular Genetics, s. 1447-1456, 2016

• DOI för Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome

Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

Velders, Matthijs A.; Wallentin, Lars; Becker, Richard C.; van Boven, Adrianus J. et al.

Ingår i American Heart Journal, s. 879-8890000000, 2015

• DOI för Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial
• Ladda ner fulltext (pdf) av Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial

Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr

Lindholm, Daniel; Storey, Robert F.; Christersson, Christina; Halvorsen, Sigrun et al.

Ingår i American Heart Journal, s. 465-470, 2015

• DOI för Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Lindholm, Daniel; Varenhorst, Christoph; Cannon, Christopher P.; Harrington, Robert A. et al.

Ingår i European Heart Journal, s. 2083-2093, 2014

• DOI för Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
• Ladda ner fulltext (pdf) av Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Wallentin, Lars; Lindholm, Daniel; Siegbahn, Agneta; Wernroth, Lisa et al.

Ingår i Circulation, s. 293-303, 2014

• DOI för Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Crona, Joakim; Fanola, Irina; Lindholm, Daniel P.; Antonodimitrakis, Pantelis et al.

Ingår i Neuroendocrinology, s. 151-155, 2013

• DOI för Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

Lindholm, Daniel P; Eriksson, Barbro; Granberg, Dan

Ingår i Medical Oncology, s. 301-303, 2012

• DOI för Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

Early diagnosis of acute coronary syndrome

Katus, Hugo; Ziegler, André; Ekinci, Okan; Giannitsis, Evangelos et al.

Ingår i European Heart Journal, s. 3049-3055, 2017

• DOI för Early diagnosis of acute coronary syndrome

Bioresorbable Stents in PCI

Lindholm, Daniel; James, Stefan

Ingår i Current Cardiology Reports, 2016

• DOI för Bioresorbable Stents in PCI

Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Lindholm, Daniel P; Öberg, Kjell

Ingår i Hormone and Metabolic Research, s. 832-837, 2011

• DOI för Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors

Platelet Inhibition, Revascularization, and Risk Prediction in Non-ST-elevation Acute Coronary Syndromes

Lindholm, Daniel

2015

• Ladda ner fulltext (pdf) av Platelet Inhibition, Revascularization, and Risk Prediction in Non-ST-elevation Acute Coronary Syndromes